Assignee
ARRIEN PHARMACEUTICALS LLC
US·13 granted patents·50 citations·filing 2013–2019
Top patents by PatentIndex Score
13 records- 0195US9669028B2Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2015·Granted Jun 6, 2017·30 cites·12 claims
- 0285US9951062B2Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2015·Granted Apr 24, 2018·3 cites·4 claims
- 0385US9890153B2Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2015·Granted Feb 13, 2018·4 cites·10 claims
- 0484US9260426B2Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2013·Granted Feb 16, 2016·4 cites·2 claims
- 0581US9359315B2Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosisARRIEN PHARMACEUTICALS LLC·Filed 2014·Granted Jun 7, 2016·4 cites·9 claims
- 0678US9206188B2Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2014·Granted Dec 8, 2015·5 cites·26 claims
- 0767US10682358B2Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosisARRIEN PHARMACEUTICALS LLC·Filed 2019·Granted Jun 16, 2020·0 cites·17 claims
- 0864US9187473B2Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2014·Granted Nov 17, 2015·0 cites·14 claims
- 0963US10172866B2Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosisARRIEN PHARMACEUTICALS LLC·Filed 2016·Granted Jan 8, 2019·0 cites·21 claims
- 1063US9446047B2Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosisARRIEN PHARMACEUTICALS LLC·Filed 2016·Granted Sep 20, 2016·0 cites·11 claims
- 1155US9962382B2Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2015·Granted May 8, 2018·0 cites·4 claims
- 1252US11053221B2Substituted pyrimidines for inhibiting embryonic leucine zipper kinase activityARRIEN PHARMACEUTICALS LLC·Filed 2019·Granted Jul 6, 2021·0 cites·22 claims
- 1345US9834551B2Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitorsARRIEN PHARMACEUTICALS LLC·Filed 2015·Granted Dec 5, 2017·0 cites·20 claims
Join the waitlist — get patent alerts
Get an alert when ARRIEN PHARMACEUTICALS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →